REAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
REAX is not a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 ready to deploy. The setup is mixed to weak: the technical trend is still bearish, there is no strong proprietary buy signal, hedge funds have been net sellers, and the near-term pattern bias points lower. While analyst coverage remains generally positive and the company has strategic upside from its Re/Max deal, the current entry does not look strong enough to justify an immediate long-term buy.
Current pre-market price is 1.78, up 1.71%. The technical picture is not favorable overall: SMA_200 > SMA_20 > SMA_5 confirms a bearish moving-average structure, meaning the longer-term trend still dominates to the downside. MACD histogram is slightly positive at 0.0113 and expanding, which suggests a short-term bounce attempt, but RSI_6 at 37.375 remains weak and below a strong bullish zone. Key levels show pivot at 1.744, resistance at 1.828 and 1.88, with support at 1.66 and 1.608. With the stock still trading under nearby resistance and the modeled trend implying downside over the next day/week/month, the current technical setup is not a clean long-term entry.
Analysts remain broadly constructive, with multiple Buy ratings still in place. B. Riley kept a Buy rating and raised the target context to $7 from $8 while calling Q1 strong. BTIG views the Re/Max acquisition as a strategic positive that could improve scale, diversify revenue, and add a high-margin franchise business. The stock also has some short-term pre-market momentum and call-heavy options positioning. No negative news was reported in the last week, so the lack of fresh bad headlines is a mild stabilizer.
There is no recent news catalyst from the past week to drive upside. Hedge funds are selling aggressively, and insider activity is neutral. Analyst targets have been cut over time, including BTIG lowering its target from $6 to $4.50 and then $4.25, and Zelman downgrading to Neutral. The company is still facing a cloudy existing-home-sales backdrop, and the stock trend model suggests negative returns over the next day, week, and month. The weak technical structure and lack of a strong Intellectia buy signal are also negative.
No usable latest-quarter financial snapshot was provided because the financial data field returned an error. Because of that, I cannot reliably assess revenue, earnings, or margin growth for the latest quarter season from the supplied data.
Analyst sentiment is mixed but still tilted positive overall. Recent views include B. Riley maintaining Buy while lowering the target to $7, BTIG keeping Buy with a $4.25 target and calling the Re/Max acquisition strategically attractive, Benchmark initiating Buy at $5.50, and JonesResearch reiterating Buy at $5. On the bearish side, Zelman downgraded to Neutral with a $3 target, and BTIG has repeatedly trimmed targets as the recovery outlook stayed cloudy. Wall Street pros see strategic consolidation upside and possible undervaluation, while the cons are slower housing recovery expectations, multiple compression, and a weaker near-term setup.
